Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia
Phase of Trial: Phase III
Latest Information Update: 05 Nov 2014
At a glance
- Drugs CYD TDV (Primary)
- Indications Dengue
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Sanofi; sanofi pasteur
- 14 Oct 2013 Results published in Vaccine.
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History